Introducing Glenn™: The Future of MRI-Compatible Robotics in Prostate Cancer Treatment

Insight Medbotics, a pioneering company in interventional oncology, is set to unveil Glenn™, its revolutionary next-generation robotic system designed specifically for prostate cancer care. This innovative MRI-compatible robot is designed to help urologists perform procedures with unprecedented precision. Leveraging prior advancements in MRI-compatible robotics, Glenn™ aims to elevate the standard of care in prostate cancer treatment by providing real-time imaging within an MRI environment.

Glenn™ takes advantage of IGAR technology, which is uniquely cleared by the FDA for use with MRI scanners, making it the first of its kind. This system digitizes the entire care process, offering urologists critical, data-driven insights that traditional ultrasound methods cannot provide. By enabling enhanced access to MRI guidance, Glenn™ eliminates the uncertainties of conventional ultrasound-guided procedures, shifting the focus toward accuracy and efficiency.

Fazila Seker, CEO of Insight Medbotics, emphasized the growing interest among urologists who have experienced the Glenn™ demonstration. According to Seker, the interest is palpable, and the feedback from practicing clinicians has been overwhelmingly positive. They see the potential of Glenn™ to facilitate needle-based procedures such as biopsies and focal therapies with greater speed and accuracy.

A notable feature of Glenn™ is its capability to avoid the use of rectal probes, a significant concern for many patients undergoing prostate treatments. Urologists have expressed a wish to mitigate discomfort, making Glenn™ an appealing option for both practitioners and patients alike.

In recent developments, Insight Medbotics has collaborated with leading urologists to refine the design of Glenn™ through continuous feedback. Dr. Edward Matsumoto has joined the Board of Directors, adding valuable insight and enhancing the product's development process. Seker remarked on the importance of these partnerships: "Access to key opinion leaders allows us to refine Glenn™ to meet the exact needs of the clinicians who will ultimately use it."

Dr. Alexander Kutikov, chair of the Department of Urology at Temple Health's Fox Chase Cancer Centre, praised Glenn™ for its accuracy in biopsy procedures. He highlighted the robot's ability to record exactly where biopsies are taken, ensuring that any subsequent treatment can be accurately directed when needed. This precision is a game-changer, making targeted therapy more effective. The direct feedback from urologists ensures that the final product will align closely with the actual needs of healthcare providers and their patients, further strengthening its position in the market.

As Insight Medbotics progresses towards regulatory approval, they are also considering future expansions into markets beyond the U.S., aiming for Canada and other potential international markets once Glenn™ has received the necessary certifications. As it stands, Glenn™ is still under development and is not available for sale.

About Insight Medbotics

Insight Medbotics is committed to transforming cancer care with advanced robotics and precision targeting. Their flagship IGAR technology has already been clinically verified, and as the only company to have received FDA 510(k) clearance for MRI-compatible robotics, they are poised to lead a new era in the treatment of prostate cancer. The development of Glenn™ represents a significant leap toward achieving better outcomes and a higher quality of life for patients tackling this formidable disease. With continuous innovation and dedication to clinician feedback, Insight Medbotics is on the frontline of the ongoing battle against cancer, ensuring that future treatments are as effective and patient-friendly as possible.